%0 Journal Article
%T 乳腺癌化疗联合内分泌治疗的新进展
%A 吕海通
%A 吴智勇
%A 张泽淳
%J 肿瘤防治研究
%D 2018
%R 10.3971/j.issn.1000-8578.2018.17.0552
%X 摘要 内分泌治疗和化疗是乳腺癌全身治疗的主要手段，在乳腺癌的治疗中具有极其重要的地位。当前的临床实践中，对于激素受体阳性的乳腺癌患者，早期辅助治疗、局部晚期新辅助治疗或晚期解救治疗，无论月经状态和使用何种药物，内分泌治疗与化疗都普遍采取序贯的方式。化疗与内分泌治疗联合是否会影响疗效及药物的安全性，目前仍存在一定争论。既往的研究表明将两者同时使用并没有产生预期的疗效叠加结果，反而影响化疗疗效。但近年来一系列研究进展显示出化疗与内分泌治疗联合具有一定的临床应用价值，本文就乳腺癌化疗联合内分泌治疗的最新研究进展作一综述
%K A Predictor of Risk and Prognosis of Breast Cancer
%K Tanshinone ⅡA Enhances Chemosensitivity of Breast Cancer Cells to Doxorubicin and Related Mechanism
%K In Situ Hybridization Status of 568 Cases of HER2 Equivocal Breast Cancer
%K Apatinib Suppresses Proliferation and Induced Apoptosis of Human Breast Cancer Cell Line MDA-MB-231 Through Glycolytic Inhibition
%K Progress of Whole Exon Sequencing in Pathogenesis and Diagnosis of Breast Cancer
%K Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib
%K Influence of NRP-1 Monoclonal Antibody on Growth of Breast Cancer Xenografts in Nude Mouse
%K Expression of Circular RNA ciRS-7 and Its Effect on Invasion and Migration of Triplenegative reast Cancer Cells
%K Breast Metastasis of Primary Pulmonary Adenocarcinoma: A Report of Two Cases and Literature Review
%U http://www.zlfzyj.com/CN/abstract/abstract9114.shtml